Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone after prior atezolizumab + bevacizumab in hepatocellular carcinoma
2023-503229-21-00Phase 3Completed
- Sponsor
- Roche
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, lenvatinib and sorafenib in hepatocellular carcinoma (HCC) (4 arms), sponsored by Roche. Primary endpoint: Overall survival. Started May 2021; status: completed.
02
Drugs
atezolizumablenvatinibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-503229-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503229-21-00.